Trevi Therapeutics (NASDAQ:TRVI) Stock Price Expected to Rise, HC Wainwright Analyst Says

Trevi Therapeutics (NASDAQ:TRVI) had its target price hoisted by HC Wainwright from $7.50 to $12.50 in a research note published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other analysts have also issued reports on the stock. Raymond James upgraded shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $9.00 to $29.00 in a research note on Monday. D. Boral Capital reiterated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Friday, March 7th. Finally, Needham & Company LLC upped their target price on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday. Seven equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $15.94.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $6.30 on Monday. Trevi Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.39. The firm has a market cap of $484.26 million, a price-to-earnings ratio of -14.32 and a beta of 0.90. The company has a fifty day moving average price of $4.26 and a 200-day moving average price of $3.58.

Insider Activity at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now directly owns 76,900 shares of the company’s stock, valued at $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 24.37% of the stock is owned by company insiders.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. lifted its holdings in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after purchasing an additional 2,894 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Trevi Therapeutics during the fourth quarter valued at about $49,000. Squarepoint Ops LLC purchased a new stake in Trevi Therapeutics during the fourth quarter valued at about $58,000. Finally, Intech Investment Management LLC purchased a new stake in Trevi Therapeutics during the third quarter valued at about $63,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.